To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers
Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :
It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).
Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.
The SCBM was awarded funding from the Horizon Europe program for the ISOBIOTICS project, coordinated by Christophe Dugave. This project will enable the theoretical and practical training of 11 PhD students, including two at SCBM and one at SHFJ, on the development of innovative methods for the isotopic labeling of biodrugs
Researchers at SPI (DMTS) have identified by mass spectrometry and bioinformatics analysis several biomarkers linked to the creatine transporter deficiency disorder (CTD) using two original models : mice with the clinical characteristics of CTD subjects and brain organoids derived from CTD patient cells.
SIMoS researchers have identified and characterised an animal toxin (A-CTX-Mila) as a ligand for angiotensin II receptors, which are involved in one of the signalling pathways targeted by antihypertensive drugs. A tool of choice for studying the cellular mechanisms controlled by these receptors.
A Li2D (SPI/DMTS) team used tandem mass spectrometry to identify microorganisms in sputum samples from cystic fibrosis patients. A promising proteotyping approach that provides an expanded and unbiased view of the cystic fibrosis microbiota and could be complementary to microbiological monitoring of patients.
A SIMoS team discovered a toxin in the venom of a marine cone that it engineers into a high affinity antagonistic peptide for the melanocortin receptor, a major regulator of energy homeostasis. A step towards the development of innovative treatments for certain eating disorders
Researchers at the Joliot Institute have developed two new families of iminosydnones that allow the bio-orthogonal release of electrophilic species. These molecules constitute "building blocks" of click-and-release chemistry, useful for reactions with nucleophilic compounds contained in cells.
To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified
IBiSA, within the Frédéric Joliot Institute for Life Sciences:
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.